BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zimislecel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zimislecel\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04786262-3443@assetmemo.bio
DTSTAMP:20261121T005259Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zimislecel: Phase 3 readout est. (NCT04786262)
DESCRIPTION:Zimislecel\, phase 3\, Type 1 Diabetes.\nStudy: A Safety\, Tole
 rability\, and Efficacy Study of VX-880 and VX-017 in Participants With Ty
 pe 1 Diabetes\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zimislecel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04786262
URL:https://assetmemo.bio/drug/zimislecel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
